Hodges Capital Management Inc. Pacira Bio Sciences, Inc. Transaction History

Hodges Capital Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 21, 2022	BUY	$51.24 - $58.89 $135,786 - $156,058	2,650 Added 51.46%	7,800 $415,000
Q2 2022 Jul 28, 2022	SELL	$51.49 - $81.64 $8.37 Million - $13.3 Million	-162,562 Reduced 96.93%	5,150 $300,000
Q1 2022 May 12, 2022	SELL	$60.03 - $76.49 $14,287 - $18,204	-238 Reduced 0.14%	167,712 $12.8 Million
Q4 2021 Feb 07, 2022	BUY	$47.97 - $62.21 $8.06 Million - $10.4 Million	167,950 New	167,950 $10.1 Million
Q2 2021 Jul 06, 2021	SELL	$59.18 - $69.99 $4.45 Million - $5.27 Million	-75,245 Closed	0 $0
Q1 2021 Apr 07, 2021	BUY	$59.31 - $78.82 $4.46 Million - $5.93 Million	75,245 New	75,245 $5.27 Million
Q4 2017 Feb 06, 2018	SELL	$31.85 - $46.95 $222,950 - $328,650	-7,000 Closed	0 $0
Q3 2017 Nov 02, 2017	BUY	$35.7 - $39.5 $249,900 - $276,500	7,000	7,000 $263,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Hodges Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hodges Capital Management Inc. with notifications on news.